^125I-脱氧尿苷治疗恶性肿瘤的研究进展

The therapeutic progression of ^125I-UdR in malignant lesions

^125I是一种俄歇电子释放体，掺入细胞DNA分子后具有显著的细胞毒性，^125I-脱氧尿苷（^125I-UdR）能特异性掺入DNA合成的S期，是^125I的良好载体。大量动物实验及临床试验已证实：肿瘤局部缓慢持续或反复间断注射，^125I-UdR的抗肿瘤作用显著，且无明显全身不良反应。^125I-UdR多局部给药，同时人们也在探索联合应用其他药物和改进局部给药方式，用以评价，^125I-UdR的疗效及其安全性。

5-^125I-2-deoxyuridine（^125I-UdR） is specially incorporated into deoxyribonucleic acid during S-phase, where it releases Auger electrons, causing cell death. ^125I-UdR has been recognized as an effective carrier. On the basis of many animal experiments and clinical trials, it is proved that prolonged continuous or repeated intermittent drug infusions intratumorally leads to favorable antineoplastic efficacy with no significant systemic toxicity, ^125I-UdR is administered locoregionally in the prevailing circumstances and investigators have been searching for therapeutic efficacy and safety of ^125I-UdR when combined with other drugs or improved treatment modality locoregionally.